

Alzheimer's Disease (AD)

A study of a new medicine (semorinemab) in patients with moderate Alzheimer's disease

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT03828747 GN40040

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to two study cohorts.

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT03828747 GN40040
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years & ≤ 85 Years

Healthy Volunteers
No
